JP2011512134A5 - - Google Patents

Download PDF

Info

Publication number
JP2011512134A5
JP2011512134A5 JP2010546400A JP2010546400A JP2011512134A5 JP 2011512134 A5 JP2011512134 A5 JP 2011512134A5 JP 2010546400 A JP2010546400 A JP 2010546400A JP 2010546400 A JP2010546400 A JP 2010546400A JP 2011512134 A5 JP2011512134 A5 JP 2011512134A5
Authority
JP
Japan
Prior art keywords
peptide linker
motif
polypeptides
modified
fusion polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010546400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011512134A (ja
Filing date
Publication date
Priority claimed from GB0802978A external-priority patent/GB0802978D0/en
Priority claimed from GB0821076A external-priority patent/GB0821076D0/en
Priority claimed from GB0900539A external-priority patent/GB0900539D0/en
Application filed filed Critical
Priority claimed from PCT/GB2009/000437 external-priority patent/WO2009103965A1/en
Publication of JP2011512134A publication Critical patent/JP2011512134A/ja
Publication of JP2011512134A5 publication Critical patent/JP2011512134A5/ja
Withdrawn legal-status Critical Current

Links

JP2010546400A 2008-02-19 2009-02-18 修飾リンカー Withdrawn JP2011512134A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0802978A GB0802978D0 (en) 2008-02-19 2008-02-19 Modified linkers
GB0821076A GB0821076D0 (en) 2008-11-19 2008-11-19 Modified linkers
GB0900539A GB0900539D0 (en) 2009-01-14 2009-01-14 Modified linkers
PCT/GB2009/000437 WO2009103965A1 (en) 2008-02-19 2009-02-18 Modified linkers

Publications (2)

Publication Number Publication Date
JP2011512134A JP2011512134A (ja) 2011-04-21
JP2011512134A5 true JP2011512134A5 (enExample) 2012-04-12

Family

ID=40845701

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010546400A Withdrawn JP2011512134A (ja) 2008-02-19 2009-02-18 修飾リンカー

Country Status (4)

Country Link
US (1) US20110172165A1 (enExample)
EP (1) EP2288386A1 (enExample)
JP (1) JP2011512134A (enExample)
WO (1) WO2009103965A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0719818D0 (en) * 2007-10-11 2007-11-21 Asterion Ltd Growth hormone fusion polypeptides
JP5883653B2 (ja) * 2009-03-10 2016-03-15 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗原提示細胞ターゲティング抗ウイルスワクチン
WO2011123683A2 (en) 2010-04-02 2011-10-06 University Of Rochester Protease activated cytokines
DK2752424T3 (da) 2011-09-04 2019-11-18 Glytech Inc Glycosyleret somatostatin og lægemiddelsammensætning, der indeholder det
CN103946234B (zh) * 2011-09-04 2017-06-30 株式会社糖锁工学研究所 附加糖链的多肽和含有该多肽的医药组合物
EP2732824A1 (en) * 2012-11-16 2014-05-21 Ceva Sante Animale Compositions and methods for increasing reproduction performance in non human mammals using alpha-beta-linked follicle stimulating hormone
EP3068891A1 (en) * 2013-11-13 2016-09-21 Aequus Biopharma Inc. Engineered glycoproteins and uses thereof
KR101873201B1 (ko) * 2015-06-11 2018-07-02 주식회사 제넥신 변형된 인터루킨-7 단백질 및 이의 용도
WO2019113221A1 (en) 2017-12-06 2019-06-13 The Board Of Trustees Of The Leland Stanford Junior University Engineered proteins to enhance sensitivity of a cell to il-2
MX2020009975A (es) * 2018-03-28 2020-10-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso.
AU2019271147A1 (en) 2018-05-14 2020-12-17 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
ES2955511T3 (es) 2018-05-14 2023-12-04 Werewolf Therapeutics Inc Polipéptidos de interleucina 2 activables y métodos de uso de los mismos
CA3137512A1 (en) 2019-05-14 2020-11-19 Werewolf Therapeutics, Inc. Separation moieties and methods and use thereof
WO2021097376A1 (en) 2019-11-14 2021-05-20 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
TWI890718B (zh) 2019-12-20 2025-07-21 美商再生元醫藥公司 新穎之il2促效劑及其使用方法(一)
US20230235067A1 (en) * 2020-06-02 2023-07-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. SSTR-2 Binding Chimeric Antigen Receptors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1177215A1 (en) * 1999-05-10 2002-02-06 The Salk Institute For Biological Studies Constitutive chimeric receptors, and methods of use thereof
US7446183B2 (en) * 2000-06-16 2008-11-04 Asterion Limited Fusion protein comprising growth hormone and growth hormone receptor
JP2008507292A (ja) * 2004-07-26 2008-03-13 アステリオン・リミテッド リンカー

Similar Documents

Publication Publication Date Title
JP2011512134A5 (enExample)
HRP20170958T1 (hr) Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6- sialilaciju
JP2011520976A5 (enExample)
JP2010143932A5 (enExample)
DK2378921T4 (da) Sammensat element, multilagsplade og panelformet element til at danne det sammensatte element
JP2011508438A5 (enExample)
SI2173381T1 (sl) Fc receptor-vezavni polipeptidi z modificiranimi efektorskimi funkcijami
JP2013523703A5 (enExample)
JP2011501007A5 (enExample)
JP2012531046A5 (enExample)
JP2011526809A5 (enExample)
CR10523A (es) Cepa bg1 de thermoanaerobacter mathranii
JP2010505891A5 (enExample)
EP2558306A4 (en) DIGITAL INJECTED DESIGN IN POWDER SURFACES
SI2470518T1 (sl) Derivati 2,5-furan dikarboksilata in njihova uporaba kot plastifikatorji
IL214648A0 (en) Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
WO2006131564A3 (de) Neue cystein-verarmte hydrophobinfusionsproteine, deren herstellung und verwendung
SG172333A1 (en) Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof
EP2382311A4 (en) POLYPEPTIDES WITH XYLANASE ACTIVITY
WO2007115724A3 (en) Method of increasing the in vivo recovery of therapeutic polypeptides
IL209304A0 (en) Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
JP2007510403A5 (enExample)
WO2008005470A3 (en) Polypeptides that bind membrane proteins
JP2012532753A5 (enExample)
WO2009081170A3 (en) Peptide fusion proteins